A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Public ClinicalTrials.gov record NCT01988961. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis
Study identification
- NCT ID
- NCT01988961
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Interventions
- Golimumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Jan 31, 2015
- Completion
- Dec 31, 2015
- Last update posted
- Jan 4, 2017
2013 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | La Jolla | California | — | — |
| Not listed | National City | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Golden | Colorado | — | — |
| Not listed | Maitland | Florida | — | — |
| Not listed | Winter Park | Florida | — | — |
| Not listed | Zephyrhills | Florida | — | — |
| Not listed | Suwanee | Georgia | — | — |
| Not listed | Idaho Falls | Idaho | — | — |
| Not listed | Crestview Hills | Kentucky | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Kansas City | Missouri | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Chesapeake | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01988961, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2017 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01988961 live on ClinicalTrials.gov.